Cohance Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences Limited is seeking shareholder approval via postal ballot for appointing Mr. Umang Vohra as Chairman (effective May 1, 2026) and Group Chief Executive Officer (effective May 20, 2026). Mr. Vohra joins from Cipla Limited where he served as Managing Director and Global CEO for over 10 years, with prior experience at Dr. Reddy's Laboratories as CFO and head of North America generics. The company also seeks approval to pay him remuneration exceeding statutory limits under Section 197 of the Companies Act. Additionally, shareholders are asked to approve a new Employee Stock Option Plan 2026 (ESOP 2026) covering up to 2,59,18,613 equity shares, its extension to unlisted subsidiaries, and grants exceeding 1% of issued capital in a single financial year. Voting period runs from May 15 to June 13, 2026.
This is a significant leadership transition bringing an experienced pharmaceutical executive to drive company transformation. The large ESOP pool signals retention focus but will dilute shareholder value. The 1% annual grant threshold for Mr. Vohra represents substantial equity compensation.